Ernexa Therapeutics Inc.

ERNA

$4.46

-1.55%

2026-09-04 11:10:32 EDT-$0.07

Healthcare

Biotechnology

NASDAQ

Active Trading

Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced ...

Price Action of ERNA

$4.46

-1.55%-$0.07

High—

Low—

52W High-90.7%

Rel. vol—

Interval

Range26m

Volume—SMA5SMA10

—

Key Metrics of ERNA

Snapshot

Latest / TTM · 6 periods

Market Cap

$5.20M

ROCE

-346.9%

EV / EBITDA

0.19x

-4.5% YoY

FCF Yield

-640.9%

-547.7% YoY

Cash Conversion Cycle

-5835.8d

Current Ratio

2.01

Quick take

Financial Highlights of ERNA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.23x

n/a

Debt / Equity

0.11

n/a

Current Ratio

2.01

Dividend Yield

0.0%

Understanding

Calendar of ERNA

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-3.84 · Revenue $0.00 · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-4.76 · Revenue $0.00 · 1 analysts

Financial Statements of ERNA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Insider Transactions of ERNA

Acquisitions (A)

Since Feb 10, 2026

Disposals (D)

Since Feb 10, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Leadership Team of ERNA

5 executives

Name	Title	Compensation	Gender	Year Born	Status
Sanjeev Luther	Chief Executive Officer, President & Director	USD 564,000	Male	1962	Active
Sandra Gurrola	Senior VP of Finance	USD 286,000

Recent News of ERNA

GlobeNewsWire8/27/2026Neutral

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available here

Historical Employee Count of ERNA

Current

Change

-16.67%

Minimum

Maximum

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-56.00 vs -4050.00	+98.6%	-3.40 vs -3.30	-3.0%
Revenue Surprise	$0 vs $32.8M	-100.0%	—	—

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	5	10-K	Mar 13, 2026	View
Dec 31, 2024	6	10-K	Mar 12, 2025	View
Dec 31, 2023	8	10-K	Mar 14, 2024	View
Dec 31, 2022	9	10-K	Mar 20, 2023	View

Date	Executive	Title	Security	Side	Shares	Price
Aug 31, 2026	Bristol James Arthur	director	Stock Option (Right to buy)	A	8,320	$4.57
Aug 31, 2026	Bristol James Arthur	director	Stock Option (Right to buy)	A	5,083	$4.57
Aug 31, 2026	Cicala Peter	director	Stock Option (Right to buy)	A	5,943	$4.57
Aug 31, 2026	Cicala Peter	director	Stock Option (Right to buy)	A	5,083	$4.57
Aug 31, 2026	Polinsky David	director	Stock Option (Right to buy)	A	5,083	$4.57

Ernexa Therapeutics Inc.

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Related stocksBiotechnology

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies

Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy

Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported

Recent Filings